News | February 23, 2024
AstraZeneca completes acquisition of Gracell
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The company has received five final approvals
Furthering cell therapy ambition across oncology and autoimmune diseases
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Subscribe To Our Newsletter & Stay Updated
